Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

Bart Barlogie, Elias Anaissie, Jeffrey Haessler, Fritz Van Rhee, Mauricio Pineda-Roman, Klaus Hollmig, Yazan Alsayed, Joshua Epstein, John D. Shaughnessy, John Crowley

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

BACKGROUND. Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma. METHODS. By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS-CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated. RESULTS. Compared with not achieving CR (NON-CR) and especially achieving and subsequently losing CR status (LOS-CR) within a 3-year landmark from treatment initiation, SUS-CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001). CONCLUSIONS. In all 3 trial settings the survival benefit of SUS-CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS-CR should be evaluated as a primary trial endpoint in high-risk myeloma.

Original languageEnglish (US)
Pages (from-to)355-359
Number of pages5
JournalCancer
Volume113
Issue number2
DOIs
StatePublished - Jul 15 2008

Fingerprint

Multiple Myeloma
Survival
Therapeutics
Metaphase
Transplants

Keywords

  • Complete remission
  • Myeloma
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Barlogie, B., Anaissie, E., Haessler, J., Van Rhee, F., Pineda-Roman, M., Hollmig, K., ... Crowley, J. (2008). Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer, 113(2), 355-359. https://doi.org/10.1002/cncr.23546

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. / Barlogie, Bart; Anaissie, Elias; Haessler, Jeffrey; Van Rhee, Fritz; Pineda-Roman, Mauricio; Hollmig, Klaus; Alsayed, Yazan; Epstein, Joshua; Shaughnessy, John D.; Crowley, John.

In: Cancer, Vol. 113, No. 2, 15.07.2008, p. 355-359.

Research output: Contribution to journalArticle

Barlogie, B, Anaissie, E, Haessler, J, Van Rhee, F, Pineda-Roman, M, Hollmig, K, Alsayed, Y, Epstein, J, Shaughnessy, JD & Crowley, J 2008, 'Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma', Cancer, vol. 113, no. 2, pp. 355-359. https://doi.org/10.1002/cncr.23546
Barlogie B, Anaissie E, Haessler J, Van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer. 2008 Jul 15;113(2):355-359. https://doi.org/10.1002/cncr.23546
Barlogie, Bart ; Anaissie, Elias ; Haessler, Jeffrey ; Van Rhee, Fritz ; Pineda-Roman, Mauricio ; Hollmig, Klaus ; Alsayed, Yazan ; Epstein, Joshua ; Shaughnessy, John D. ; Crowley, John. / Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. In: Cancer. 2008 ; Vol. 113, No. 2. pp. 355-359.
@article{e11bc7dccd4f479bae4088e0a5074b71,
title = "Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma",
abstract = "BACKGROUND. Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma. METHODS. By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS-CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated. RESULTS. Compared with not achieving CR (NON-CR) and especially achieving and subsequently losing CR status (LOS-CR) within a 3-year landmark from treatment initiation, SUS-CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001). CONCLUSIONS. In all 3 trial settings the survival benefit of SUS-CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS-CR should be evaluated as a primary trial endpoint in high-risk myeloma.",
keywords = "Complete remission, Myeloma, Prognosis",
author = "Bart Barlogie and Elias Anaissie and Jeffrey Haessler and {Van Rhee}, Fritz and Mauricio Pineda-Roman and Klaus Hollmig and Yazan Alsayed and Joshua Epstein and Shaughnessy, {John D.} and John Crowley",
year = "2008",
month = "7",
day = "15",
doi = "10.1002/cncr.23546",
language = "English (US)",
volume = "113",
pages = "355--359",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

AU - Barlogie, Bart

AU - Anaissie, Elias

AU - Haessler, Jeffrey

AU - Van Rhee, Fritz

AU - Pineda-Roman, Mauricio

AU - Hollmig, Klaus

AU - Alsayed, Yazan

AU - Epstein, Joshua

AU - Shaughnessy, John D.

AU - Crowley, John

PY - 2008/7/15

Y1 - 2008/7/15

N2 - BACKGROUND. Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma. METHODS. By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS-CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated. RESULTS. Compared with not achieving CR (NON-CR) and especially achieving and subsequently losing CR status (LOS-CR) within a 3-year landmark from treatment initiation, SUS-CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001). CONCLUSIONS. In all 3 trial settings the survival benefit of SUS-CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS-CR should be evaluated as a primary trial endpoint in high-risk myeloma.

AB - BACKGROUND. Complete response (CR) has been considered a necessary although not sufficient early clinical endpoint for extended survival in multiple myeloma. METHODS. By using Total Therapy 2 (TT2) clinical outcome data in 668 patients, whether sustained CR (SUS-CR) was potentially a superior surrogate for survival than attaining CR status per se was evaluated. RESULTS. Compared with not achieving CR (NON-CR) and especially achieving and subsequently losing CR status (LOS-CR) within a 3-year landmark from treatment initiation, SUS-CR was associated with highly superior postlandmark survival (P < .0001). These results were validated in 231 untreated patients enrolled in the predecessor trial, TT1 (hazard ratio [HR] = 0.54, P = .013) and in 1103 previously treated patients on other transplant protocols (HR = 0.49; P < .001). CONCLUSIONS. In all 3 trial settings the survival benefit of SUS-CR was independent of metaphase abnormalities as a dominant adverse parameter. Given its bleak prognosis despite high CR rates, SUS-CR should be evaluated as a primary trial endpoint in high-risk myeloma.

KW - Complete remission

KW - Myeloma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=48249127515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48249127515&partnerID=8YFLogxK

U2 - 10.1002/cncr.23546

DO - 10.1002/cncr.23546

M3 - Article

C2 - 18470907

AN - SCOPUS:48249127515

VL - 113

SP - 355

EP - 359

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -